Trials / Completed
CompletedNCT01898715
Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Millendo Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human study is designed to establish the safety and tolerability of ATR-101 in patients with advanced adrenocortical carcinoma whose tumor has progressed on standard therapy. Information will also be collected to determine how long ATR-101 stays in the blood, and if any effect on tumor progression is seen. Biomarkers (blood and urine tests) will determine if any effects on production of steroid hormones (cortisol, aldosterone, estrogen and testosterone) are seen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATR-101 |
Timeline
- Start date
- 2013-08-13
- Primary completion
- 2016-11-02
- Completion
- 2017-10-17
- First posted
- 2013-07-12
- Last updated
- 2017-11-06
Locations
5 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT01898715. Inclusion in this directory is not an endorsement.